MediBeacon completes trial of transdermal glomerular filtration rate monitor

MediBeacon, a company within the Pansend Life Sciences platform of HC2 Holdings, has released the results of a clinical trial testing the effectiveness of its Transdermal Glomerular Filtration Rate ("GFR") Monitor on patients with ranging kidney function.

Moving toward real-time measurements, the monitor uses optical skin sensors with a fluorescent tracer agent that glows under light. This device is able to give physicians continuous measurements of kidney function without the need to take blood.

"Completion of our clinical study on patients with impaired kidney function represents an important milestone," said Steve Hanley, MediBeacon CEO.  "We anticipate beginning our multicenter clinical study including sites in the United States and Europe during the fourth quarter 2017."

"Methods to assess kidney function have not changed in 25 years," said Richard Solomon, a professor at the University of Vermont College of Medicine.  "MediBeacon's point of care system could represent a major breakthrough in measuring kidney function."